Published in Medscape J Med on June 03, 2008
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol (2010) 0.91
The role of CD95 and CD95 ligand in cancer. Cell Death Differ (2015) 0.88
Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol (2014) 0.85
Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One (2013) 0.82
The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hepat Mon (2012) 0.81
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol (2016) 0.77
Therapeutic efficacy of brucea javanica oil emulsion (BJOE) combined with transcatheter hepatic arterial chemoembolization (TACE) in patients with primary liver cancer. Int J Clin Exp Med (2015) 0.76
Expression of cluster of differentiation-95 and relevant signaling molecules in liver cancer. Mol Med Rep (2014) 0.75
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (1994) 3.98
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology (1994) 1.80
Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol (1995) 1.71
Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int (2007) 1.51
Suppression of apoptotic cell death by hepatitis C virus core protein. Virology (1996) 1.46
Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology (1997) 1.41
Hepatitis C virus infection and apoptosis. World J Gastroenterol (2007) 1.36
HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med (2005) 1.20
Death receptor-mediated liver injury. Semin Liver Dis (2007) 1.18
Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res (1996) 1.13
Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (2005) 1.11
Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol (1996) 1.07
Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood (1995) 1.06
Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett (1995) 1.05
Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol (1999) 1.05
Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology (2005) 0.99
Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol (1997) 0.99
Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol (1998) 0.98
Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res (1996) 0.97
Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction. Lab Invest (1998) 0.85
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed (2007) 0.85
Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol (2001) 0.85
The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res (2002) 0.84
Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J Int Med Res (2003) 0.83
Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg (2004) 0.82
The effects of interleukin-10 on the expression of Fas and FasL in rat hepatic stellate cells. Med Chem (2006) 0.82
Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy. J Clin Gastroenterol (2002) 0.80
Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol (2003) 0.80
Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases. East Afr Med J (1995) 0.79
[Primary liver cancer. Its epidemiological, clinical and biochemical characteristics]. Rev Gastroenterol Mex (1994) 0.79
Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol (1997) 0.78
Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy. J Gastroenterol (2004) 0.78
Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol (2007) 0.78
[Apoptosis and progression of hepatic fibrosis in liver diseases]. Acta Gastroenterol Latinoam (2006) 0.77
CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS (2010) 0.90
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed (2007) 0.85
Immunological and parasitological parameters after treatment with dexamethasone in murine Schistosoma mansoni. Mem Inst Oswaldo Cruz (2010) 0.82
Effect of combined chemotherapy and anti-inflammatory drugs on murine schistosomiasis. Arzneimittelforschung (2002) 0.79
Monocyte adhesion molecules expression in patients with chronic hepatitis C liver disease. Mediterr J Hematol Infect Dis (2013) 0.76
ROLE OF EPITHELIAL MESENCHYMAL TRANSITION IN HEPATIC FIBROGENESIS. J Egypt Soc Parasitol (2015) 0.75
ROLE OF T REGULATORY CELLS IN CHRONIC HCV INFECTED EGYPTIAN PATIENTS AND THEIR IMPACT ON THE RESPONSE TO PEGYLATED INTERFERON THERAPY. J Egypt Soc Parasitol (2015) 0.75
Transplant of Hepatocytes, Undifferentiated Mesenchymal Stem Cells, and In Vitro Hepatocyte-Differentiated Mesenchymal Stem Cells in a Chronic Liver Failure Experimental Model: A Comparative Study. Exp Clin Transplant (2017) 0.75
Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates. APMIS (2006) 0.75